Literature DB >> 27979738

Chronic blockade of the AT2 receptor with PD123319 impairs insulin signaling in C57BL/6 mice.

M C Muñoz1, V Burghi1, J G Miquet1, I A Cervino1, D T Quiroga1, L Mazziotta1, F P Dominici2.   

Abstract

The renin-angiotensin system modulates insulin action. Angiotensin type 1 receptor exerts a deleterious effects while the angiotensin type 2 receptor (AT2R) appears to have beneficial effects providing protection against insulin resistance and type 2 diabetes. Although recent reports indicate that agonism of AT2R ameliorates diabetes and insulin resistance, the phenotype of AT2R-knockout mice seems to be controversial relating this aspect. Thus, in this study we have explored the role of AT2R in the control of insulin action. To that end, C57Bl/6 mice were administered the synthetic AT2R antagonist PD123319 for 21days (10mg/kg/day ip); vehicle treated animals were used as control. Glucose tolerance, metabolic parameters, in vivo insulin signaling in main insulin-target tissues as well as levels of adiponectin, TNF-α, MCP-1 and IL-6 in adipose tissue were assessed. AT2R blockade with PD123319 induced a marginal effect on glucose homeostasis but an important reduction in the insulin-induced phosphorylation of the insulin receptor and Akt in both liver and adipose tissue. Insulin signaling in skeletal muscle remained unaltered after treatment with PD123319, which could explain the minimal effect on glucose homeostasis induced by PD123319. Our current results reinforce the notion that the AT2R has a physiological role in the conservation of insulin action.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiotensin II; Angiotensin type 2 receptor; Glucose tolerance; Insulin; Renin-angiotensin system

Mesh:

Substances:

Year:  2016        PMID: 27979738     DOI: 10.1016/j.peptides.2016.12.003

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  7 in total

1.  Role of angiotensin II type 1 (AT1) and type 2 (AT2) receptors in airway reactivity and inflammation in an allergic mouse model of asthma.

Authors:  Mehaben Patel; Mangesh Kurade; Sahith Rajalingam; Riya Bhavsar; S Jamal Mustafa; Dovenia S Ponnoth
Journal:  Immunopharmacol Immunotoxicol       Date:  2019-05-07       Impact factor: 2.730

2.  Mice lacking angiotensin type 2 receptor exhibit a sex-specific attenuation of insulin sensitivity.

Authors:  Diego T Quiroga; Johanna G Miquet; Lorena Gonzalez; Ana I Sotelo; Marina C Muñoz; Pedro M Geraldes; Jorge F Giani; Fernando P Dominici
Journal:  Mol Cell Endocrinol       Date:  2019-09-17       Impact factor: 4.102

Review 3.  Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity.

Authors:  Guanghong Jia; Michael A Hill; James R Sowers
Journal:  Circ Res       Date:  2018-02-16       Impact factor: 17.367

Review 4.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

Review 5.  Angiotensin II Type 2 Receptor: A Target for Protection Against Hypertension, Metabolic Dysfunction, and Organ Remodeling.

Authors:  Naureen Fatima; Sanket N Patel; Tahir Hussain
Journal:  Hypertension       Date:  2021-04-12       Impact factor: 10.190

6.  Chronic administration of the angiotensin type 2 receptor agonist C21 improves insulin sensitivity in C57BL/6 mice.

Authors:  Diego Tomás Quiroga; Marina C Muñoz; Carolina Gil; Marlies Pffeifer; Jorge E Toblli; Ulrike M Steckelings; Jorge F Giani; Fernando P Dominici
Journal:  Physiol Rep       Date:  2018-08

Review 7.  Unraveling and Targeting Myocardial Regeneration Deficit in Diabetes.

Authors:  Claudia Molinaro; Luca Salerno; Fabiola Marino; Mariangela Scalise; Nadia Salerno; Loredana Pagano; Antonella De Angelis; Eleonora Cianflone; Daniele Torella; Konrad Urbanek
Journal:  Antioxidants (Basel)       Date:  2022-01-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.